Patents
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
03/2008
03/18/2008US7345091 Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
03/18/2008US7345090 Galenical formulation
03/18/2008US7345089 Microbial method of making equol-containing composition and product made
03/18/2008US7345088 Synergistic mixtures
03/18/2008US7345087 Aminocyclohexyl ether compounds and uses thereof
03/18/2008US7345086 Uses of ion channel modulating compounds
03/18/2008US7345085 Indoles having anti-diabetic activity
03/18/2008US7345084 nonsteroidal progestagens; selectivity; 6-Chloro-5-fluoro-2-phenyl-3-phenylsulfanyl-1H-indole; contraceptives; amenorrhea, dysfuntional bleeding; polycysticovarian syndrome, anticancer, side effect reduction of cyclid menstrual bleeding, food intake stimulation
03/18/2008US7345083 Emesis, urinary incontinence, depression, and anxiety; substance P inhibitors; 5-{1-[3,5-bis(Trifluoromethyl)phenyl]ethoxy}-4-(4-fluorophenyl)octahydro-1H-isoindole
03/18/2008US7345082 Phosphinic acids
03/18/2008US7345081 Azabicyclo-octane inhibitors of IAP
03/18/2008US7345079 Treatment of disorder related to low cyclic GMP levels
03/18/2008US7345078 NF-κB inhibitors and uses thereof
03/18/2008US7345077 4-(substituted cycloalkylmethyl) imidazole-2-thiones, 4-(substituted cycloalkenylmethyl) imidazole-2-thiones, 4- (substituted cycloalkylmethyl) imidazol-2-ones and 4- (substituted cycloalkenylmethyl) imidazol-2-ones and related compounds
03/18/2008US7345075 1,2 diarylbenzimidazoles and their pharmaceutical use
03/18/2008US7345074 Derivatives of [6,7-dihydro-5H-imidazol[1,2-a]imidazole-3-sulfonylamino]-propionamide
03/18/2008US7345073 Method for treating cryptorchidism
03/18/2008US7345072 As precursors for angiotensin II antagonists; deprotecting the reactive tetrazole nitrogen an anhydrous or concentrated aqueous solution of a hydrohalic acid to obtain the active antagonist
03/18/2008US7345071 Process for the synthesis of Losartan potassium
03/18/2008US7345070 Side effects reduction; Diabetes mellitus, Syndrome X, Type II diabetes, hyperglycemia, hyperlipidemia, obesity, coagaulopathy, hypertension, atherosclerosis; 3-{4-[2-(2-phenyl-5-methyl-oxazol-4-yl)-ethoxy]-phenyl}-2-methyl-2-phenoxy-propionic acid
03/18/2008US7345069 Oxidative activation and episulfonium ion-mediated DNA alkylation-based anticancer
03/18/2008US7345068 Aromatic amino acid derivatives and medicinal compositions
03/18/2008US7345067 peroxisome proliferator activators such as (2-methyl-4-{methyl-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-ylmethyl]-amino}-phenoxy)-acetic acid, used as lipid modulators and insulin sensitizers
03/18/2008US7345066 Use of thiazole derivatives for preparing a medicine for protecting mitochondria
03/18/2008US7345065 Using adrenergic receptors; side effect reduction
03/18/2008US7345064 5-(4-pyridyl)valeric acid N-[2-(1-adamantyl)ethyl]-N-pentylamide; Autoimmune diseases such as rheumatoid arthritis, allergy and diabetes
03/18/2008US7345063 Amides, preparation and therapeutic use as modulators of CCR-receptor activity
03/18/2008US7345062 Substituted acylhydroxamic acids and method of reducing TNFαlevels
03/18/2008US7345061 Alkylammonium salts of omeprazole and esomeprazole
03/18/2008US7345060 E.g., biphenyl-2-ylcarbamic acid 1-{9-[2-(4-hydroxy-2-oxo-2,3-dihydrobenzothiazol-7-yl)ethylamino]nonyl}piperidin-4-yl ester;respiratory system disorders; bronchodilators; chronic obstructive pulmonary disease or asthma; affinity for dopamine D2 receptors; used with phosphodiesterase-4 inhibitor
03/18/2008US7345059 Diphenylpyridine derivatives, preparation and therapeutic application thereof
03/18/2008US7345058 Pyrazoles
03/18/2008US7345057 5-HT7 receptor antagonists
03/18/2008US7345056 Bridged N-cyclic sulfonamido inhibitors of gamma secretase
03/18/2008US7345055 2,7-dimethylimidazo[1,2- alpha ]pyridin-3-ylmethyl)-dimethylamine; nitric oxide synthase inhibitor; neurodegenerative diseases and antiinflammatory, antitumor agent; multiple sclerosis, Parkinson's, Alzheimer's or Huntington's disease, cerebral ischemia, diabetes, meningitis, angiogenesis,
03/18/2008US7345054 Heterocyclic inhibitors of ERK2 and uses thereof
03/18/2008US7345053 Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
03/18/2008US7345052 Arylindenopyridines and arylindenopyrimidines and related therapeutic and prophylactic methods
03/18/2008US7345051 For controlling mucin over-production associated with diseases such as chronic obstructive pulmonary diseases including asthma and chronic bronchitis, inflammatory lung diseases, cystic fibrosis and acute or chronic respiratory infections
03/18/2008US7345050 Imidazo(1,2a)pyridine or pyrazolo(2,3a)pyridine derivatives; Alzheimer's and Parkinson's Disease; nervous system, brain, and psychological disorders
03/18/2008US7345049 Phenylalanine derivatives
03/18/2008US7345048 Heterocyclic compounds and uses thereof as D-alanyl-D-alanine ligase inhibitors
03/18/2008US7345047 7-[7-[2-cycloalkyl]amino]-5-(propylthio)--3H-[1,2,3]triazolo[4,5-d]pyrimidin-3-yl]spiro[2.4]heptane-4,5,6-triol from spiro[2.4]hept-5-ene-4,7diol Diacetate and 4,6-dichloro-5-nitro-3-propylthiopyrimidine intermediates; for P2T (P2Y(ADP) or P2T(AC)) receptor antagonists; antithrombotics; unstable angina
03/18/2008US7345046 Using quinazoline type compound ; antiproliferative agents
03/18/2008US7345045 Pyrido-pyrimidine compounds as medicaments
03/18/2008US7345044 Sodium channel blockers
03/18/2008US7345043 Inhibitors of histone deacetylase
03/18/2008US7345042 Piperazine derivatives; melanin concentrating hormone (MCH) receptor modulators; metabolic and/or eating disorders, diabetes
03/18/2008US7345041 Chemical compounds
03/18/2008US7345040 Piperimido[1,2-a]piperazine-4,7diones derivatives; neurokinin (tachykinin) receptor antagonists; mimic the secondary structure of reverse-turn regions of biologically active peptides and proteins; analgesic, neurodegenerative disorders, respiratory diseases, antiinflammatory agent, antidepressant
03/18/2008US7345039 Enhancement of effectiveness of 5-fluorouracil in treatment of tumor metastases and cancer
03/18/2008US7345038 Pyridyloxymethyl and benzisoxazole azabicyclic derivatives
03/18/2008US7345037 ipratropium/flutropium/tiotropium derivatives; anticholinergic agent; linked at NO or NO2 group, or group which stimulates endogenous production of NO; beneficial therapeutic effects; asthma, respiratory disorder, cystic fibrosis; synergistic with NO release agent or substrate for nitric oxide synthase
03/18/2008US7345036 (Pyrido/thieno)—[f]—oxazepine-5-one derivatives
03/18/2008US7345035 Downregulating mRNA encoding osteopontin by administering to a cell or mammal an effective amount of astrogorgiadiol; treatment of osteoporosis, systemic lupus erythematosis or multiple sclerosis
03/18/2008US7345034 1-[3-(8-methyl-5,6,6a,7,8,9,10,11-octahydro-4bH-benzo[4,5]indeno[1,7a-c]pyrrol-2-yl)-phenyl]-ethanone; histaminergic nerve endings and neurons with adrenergic, cholinergic, serotoninergic, and dopaminergic activity; memory and cognition processes, neurological processes, cardiovascular function
03/18/2008US7345033 Carbamoyl-and thiocarbamoyl-phosphonates and pharmaceutical compositions comprising them
03/18/2008US7345032 alkylation of 1,3-diaminopropane or addition to diethyl vinylphosphonate, to form N-(3-aminopropyl)aminoethanephosphonic acid diethyl ester, which is condensed with a squarate compound to give drugs used as N-methyl-D-aspartic acid (NMDA) antagonists
03/18/2008US7345031 for treating neurological diseases including Parkinson's and related diseases; Hydrophilic transportable N-linked glycosyl dopaminergic prodrug compounds
03/18/2008US7345030 Use of n-acetyl-d-aminoglycosamine in treatment of organ lesions related to toxicosis of drugs or chemicals
03/18/2008US7345029 Osmotic glucose polymer, electrolyte, and buffer solutions administered to patient after heat sterilization
03/18/2008US7345028 Energy-protective composition comprising adenosine phosphates
03/18/2008US7345027 Controlling gene expression using RNA preferential for endothelial growth factor genes and transmembrane tyrosine kinases; antiproliferative agents
03/18/2008US7345025 Methods for genetic modification of hematopoietic progenitor cells and uses of the modified cells
03/18/2008US7345024 Pharmaceutical preparation, method for its production as well as its use
03/18/2008US7345023 Treatment of hyperproliferative conditions of body surfaces
03/18/2008US7345018 Immobilization drug; side effect reduction
03/18/2008US7344869 Isolated DNA comprising one or more genes specific for 5S clavam biosynthesis, vectors comprising such DNA and Streptomyces hosts capable of improved clavulanic acid production
03/18/2008US7344868 Amide formation and esterification performed by lipases, between fatty acids and/or esters of fatty acids and amino-alcohols; used in the form of cosmetic and/or dermatology
03/18/2008US7344853 Methods for diagnosis and monitoring of neurological disease by detection of an encephalotoxin
03/18/2008US7344851 Anticancer agents based on prevention of protein prenylation
03/18/2008US7344736 Extraction of pharmaceutically active components from plant materials
03/18/2008US7344734 Controlling particle size; antiagglomerant
03/18/2008US7344727 Process for cleaning bovine teats
03/18/2008US7344720 Vaccine composition
03/18/2008US7344710 Aministering synergistic mixture of Clostridium spores and anticancer agents
03/18/2008US7344706 UV absorber compositions comprising a hydroxyphenyltriazine compound
03/18/2008CA2561293C Treatment of incontinence
03/18/2008CA2507743C Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles
03/18/2008CA2475113C Isothiazole derivatives useful as anticancer agents
03/18/2008CA2454328C Pharmaceutical combinations of oxycodone and naloxone
03/18/2008CA2401005C Methods for extraction and reaction using supercritical fluids
03/18/2008CA2394120C Tricyclic fused heterocyclic compound, process for preparing it and medicament comprising it
03/18/2008CA2389167C Pharmaceutical formulations of resveratrol and methods of use thereof
03/18/2008CA2388050C Antibiotic caprazamycins and process for producing the same
03/18/2008CA2382359C Pharmaceutical preparation containing nanosol
03/18/2008CA2380326C Novel 2-decarboxy-2-phosphinico prostaglandin f analogs
03/18/2008CA2379331C Ectoparasiticidal aqueous suspension formulations of spinosyns
03/18/2008CA2355776C Phospholipid complexes of proanthocyanidin a2 as antiatherosclerotic agents
03/18/2008CA2355239C Pharmaceutical formulations
03/18/2008CA2347195C Oral pharmaceutical compositions containing buprenorphin
03/18/2008CA2345248C Use of prostanoid antagonists for the treatment of primary headache disorders
03/18/2008CA2335015C Carnitine and inositol phosphate-containing composition useful as dietary supplement or drug
03/18/2008CA2332853C Dry powder dispersing apparatus and methods for their use
03/18/2008CA2329128C Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
03/18/2008CA2328955C Fetal testing for prediction of low birth weight
03/18/2008CA2327784C Triazolones with a neuroprotective action
03/18/2008CA2326441C Process for purification of a cephalosporin derivative
03/18/2008CA2323839C Treatment of neuropathy
03/18/2008CA2320430C Recombinant mistletoe lectins